Come from：Shandong Caman Biotech Co., Ltd. Class：News Date：2023/4/21 浏览统计：130 |
In early March, the National Organization of Drug Joint Procurement Office released the relevant documents of the "National Drug Centralized Procurement Document". According to the documents, the eighth batch of national procurement will begin receiving application materials at 7:30 am on March 29th, and the application information will be publicly disclosed at 10 am. The supply area will be confirmed at 2 pm. The eighth batch of domestically collected varieties involves a total of 40 major varieties, covering the fields of anti infective, heparin, antithrombotic, hypertension and other drugs. Heparin products have been included in the national collection for the first time. According to media reports, many of the varieties collected this time are large varieties with market sales exceeding 1 billion yuan. It is worth mentioning that heparin products with a larger market scale have been included in the centralized procurement for the first time this year. These drugs are widely used as anticoagulant and antithrombotic clinical drugs in the treatment of a series of diseases such as myocardial infarction, cardiovascular surgery, and hemodialysis. Industry experts have stated that although this type of drug has been included for the first time, the competition is very fierce. This will be beneficial for patients who use heparin in clinical practice to reduce medical costs. |
工商营业执照信息公示